The main objective of this research is to identify highly cited papers in clinical pharmacology and to analyze their publication and citation data to study their citation characteristics, and understand what role contri buting authors, participating research organizations as well as international collaborative countries play in Indian clinical pharmacology research. Design: The publications output of Indian clinical pharmacology papers published during 200014 were screened in Scopus database and highly cited papers, with at least 100 citations since publication, were identified and shortlisted for their bibliometric analysis. The statistics cover collabo ration across authors, institutions, foreign participating countries in the publication of highly cited papers. To assess comparative contributions of authors/ organizations, a new indicator, the Major Contributor Index (MCI), was used. Citation trends for all papers, as well as for top papers, are presented. Results: A total of 76 highly cited articles, constituting 1.45% share of world highly cited papers output and 0.75% share of India's publications output, were published by India in clinical pharmacology output during 200014. This study covered only those papers that received at least 100 citations since publication. In recent years, topcited articles have reached their citation peak in the early years of their citation life cycle, but have shown a morerapid decreasing trend compared to topcited articles from past decades. These 76 highly articles have received 14059 citations, with an average citation per paper of 184.99. The leading Indian organiza tions participating in highly cited research papers were All
INTRODUCTION
Clinical pharmacology is a relatively young discipline and involves scientific study of drugs in man, their rational use which includes personalized medicine, safety and efficacy of medicines, consideration to cost, availability, etc. In recent years, the scope of clinical pharmacology has expanded to contribute more proactively to public health, to development of drugs from bench to bedside to marketing and life thereafter. The discipline was started in India in 1960s. Since then, it has been contributing to development of new drugs, clinical research, clinical trials for new drug, new drug regimens, rational use of drugs, pharmacogenetics, etc. Contributions in these areas have come from various organizations like Council for Scientific and Industrial Research (CSIR), Indian Council of Medical Research (ICMR), the centers of excellence developed by ICMR, World Health Organization (WHO), departments in academic organizations, pharmaceutical industry, etc. However, these developments have been rather slow and inadequate to meet the future challenges. 1, 2 
Literature Review
There is no study in the literature on pharmacology and clinical pharmacology pertaining to analysis of high cited papers. However, few studies were carried out on quantitative analysis of pharmacological research output of India. Among such studies, Nayak, Mor and Unnikrishan 3 analyzed the publications of pharmacy schools in India from 1947 to 2009. It was found that the annual rate of increase in publications peaked at 30 to 40% between 2005 and 2007. Karnataka came first with more than 16% of the country's publications output with over 13% of citations. The top ten schools bagged about 52% publications and 70% citations. The break-up data placed Dr Harisingh Gour University, Sagar on top for the maximum number of publications and Panjab University for the highest citations as well as citations per paper Only 21 papers from Indian pharmacy schools have a total citation count of more than 100.
The current trend holds promise for rapid growth, although quality of publications has not yet become the priority of most researchers. The next study by Mueen Ahmad, Gupta and Gupta 4 analyzed performance of Indian pharmacological research during the last ten years using publications data covered in Scopus database, based on several parameters including global publication share and rank of 15 most productive countries, India's publication growth rate and citations impact, its pattern of citations output, international collaboration profile, institutional profile, geographical distribution of output, contribution and impact of top organizations and authors, pattern of communications and characteristics of high cited papers. In another study Gupta, Mueen Ahmad and Gupta 5 analyzed high productivity organizations in pharmaceutical science in India, using the publications data indexed and covered in Scopus database from 2008 to 2012. It identified their overall strength of these pharmaceutical organizations, measured in terms of select quantitative and qualitative indicators. It also provides a comparative evaluation and performance of different types of Indian pharmaceutical organizations. The study concludes that model of research funding of research institutes, institutes of national importance and universities is comparatively more effective in terms of quantity and quality of research performance. The paper also lists suggestions for national policy formulation for growth and development of pharmaceutical research in the country
METHODOLOGY
The study derived data on highly-cited papers from the Scopus, an international multidisciplinary bibliographical and citation database, in August 2015 and covered the period from 2005 to 2014. A highly-cited article (TC2014 ≥ 100) was defined as an article registering at least 100 citations since its publication up to August 2015. In total, there were 76 India's highly cited articles in clinical pharmacology that received at least 100 citations since publication. The impact factor (IF) of a journal was based on the Journal Citation Report (JCR) 2013. The study organized publication and citation data into groups such as: (i) first author publications (FP), (ii) corresponding author publications (RP), (iii) FP-RP. Both first and corresponding author publications, (iv) the number of citations since publication to 2014 is referred as TC2014, (v) citations received in the year of publications (C0), (vi) citations in the first year after publication (C1), (vii) the number of citations received in year 2014 is referred as C2014, (vi) national and international collaborative publications, and (vii) most productive journals, etc. The data was analyzed to assess the quantum of research under various groups, its global share, research quality, life cycle of research publications, contribution of different types of Indian authors and organizations in clinical pharmacology. Indian organizations have been classified into groups such as: (i) institutes of national importance, (ii) research institutes, (iii) universities, (iv) colleges, (v) engineering colleges, (vi) medical and allied sciences colleges, (vii) industrial enterprises and (viii) non-profitable institutions. The collaboration type was determined from addresses data of the authors. An article could be either a single-country article, in which all authors' addresses (one or more) were from the same country, or bilateral or multilateral international collaborative article, co-authored by researchers from 2 or more countries (India and other country). In a single author article where authorship is unspecified, the single author is presumed both as first author and corresponding author. Similarly, in a single institutional article, the institution is classified both as the first author institution and the corresponding author institution. In addition, only the first affiliation of corresponding author was considered when the author had multiple affiliations At the individual level, a non-alphabetical name order sends a clear signal to the market that the author who is listed first actually contributed more. The first author is the person who contributed most to the work and writing of the article. 6 The corresponding author is perceived as the author contributing significantly to the article independent of the author position. 7 The corresponding author supervised the planning and execution of the study and the writing of the paper. 8 It is generally assumed that the first author and the corresponding author played significant roles, and they are the major contributors in producing a research paper. Thus, in this research, a newly developed indicator as suggested by Chuang and Ho, 9 the MCI, was used to assess the extent to which a researcher or an institution contributed to publishing an article. The MCI is calculated as the sum of first-author articles and corresponding articles divided by 2-times the total number of articles. It implies the percentage of instances one takes on the leadership role (first author or corresponding author) out of the total possible available opportunities. The equation is:
MCI=(FP-RP)/2TP, Where FP is the number of first-author articles, RP is the number of corresponding-author articles, and TP is the number of total articles. When the MCI = 0, there is no first-or corresponding-author article. When the MCI = 1, all articles are either first-or corresponding author articles. MCI has two implications. First, it probably indicates a higher capability or productivity in conducting independent research. Second, it could, as well, indicate a more prominent role in collaborations. On the contrary, a low MCI is probably a sign of heavy reliance on collaboration, as well as relying on others to provide a leadership role in conducting research. 9
OBJECTIVES
The main objective of this study is to examine the characteristics of highly cited Indian publications in clinical pharmacology published during 15 years between 2000 and 2014. The study in particular will assess: (i) the annual distribution of Indian contributions, its research quality and its global share, (ii) the contribution made by authors and organizations from different types of Indian organizations, (iii) institutional participation measured in terms of single institution publications and collaborating institution publications; (iv) nature of international collabo ration (bilateral or multilateral), and (v) media for communication of publications and (vi) characteristics of top 10 publications.
ANALYSIS, RESULTS AND DISCUSSION

Publications Analysis
As per data sourced from SCOPUS database covering the period 2000-14, the world output of highly cited papers (HCPs) in clinical pharmacology, cited at least 100 times since their publication, stood at 5242 papers. The annual world output of highly cited papers in clinical pharmacology dropped from 2200 in 2000, the first year of this study period to 292 papers in 2014, the last year of this study period. Highly cited papers constituted 1.97% share of the world output covering all of publications in clinical pharmacology (265489 papers) during 2000-14. India ranked 10 th highest country with 1.45% share to the world output of highly cited papers in clinical pharmacology (76 HCPs). In the ranking of top 10 leading countries by their world output of highly cited papers in clinical pharmacology, the USA topped with highest world share (61.41%, 3219). The top five nations USA, U K, Germany, Italy, and Canada constituted 6.41% -61.41% share of the world output of the highly cited papers (5242 HCPs) in clinical pharmacology during 2000-14 (Table 1, Figure 1 ). India ranked 9 th highest with its highly cited papers constituting 0.75% share of the national output during 2000-14. In the national ranking of countries by their share of highly cited papers, United States topped the list with 3.85% highest national share. The top five countries --USA, U.K., Germany, Canada, and France --relatively produced 3.45% -3.85% share of their national output as highly cited papers during 2000-14. It is evident that national output of highly cited papers in India is relatively too low compared to top ranking countries. (Table 1, Figure 1 ). India ranked 7 th highest with its national output constituting 3.81% share (10108 papers) in the world output in clinical pharmacology covering all of research publications including even highly cited papers. United States topped with 31.50% global share (83629 papers) relative to 3.81% by India during 2000-2014. Annual output of highly cited papers in clinical pharmacology during 2000-14 remained range bound between 2 and 11 paper per year.
Of all the 76 highly cited papers produced by India, 30 (39.47%) appeared as articles, 43 (56.58%) as reviews and 1 (1.32%) paper each as conference papers, short surveys, letters. Unexpectedly, conference paper registered the highest citation impact per paper (593), followed by articles (200.83), reviews (165.26), Short survey (124) and Letter (121.0) during 2000-2014 ( Table 2 ).
Citations Analysis
The 76 highly cited papers under this study cumulated 14059 citations in 15 years during 2000-Aug 2015. Citation to papers has been used as a proxy for describing the quality of research, to judge how 76 highly cited papers in clinical pharmacology inter-compare in their performance on quality and impact. The citation impact of 76 highly cited papers averaged to 184.99 citations per paper in 15 years period, and citation impact of their annual output distributed across 15 publication years ranged between 129.5 and 346 citations per paper (CPP). Citation window is this study is variable since citations to papers have been counted from their publication year till August 2015. CPP as such is not a valid indicator for inter-comparing impact of 76 highly cited papers across 15 differential citation window periods. This study, therefore, used 'citation density' -another citation impact indicator -which normalizes citation window period, and measures citation impact in terms of both; (i) citations Figure 3 ). 26 The citations to highly cited papers cover a wide citation spectrum spreading across from 100 to 899 citations per paper. The distribution of highly cited papers across differential-citation frequency ranges is skewed. Bulk of highly cited papers (75%), accounting for the largest citation share (54.51%), define low-end citation frequency range (100-199 times). Nearly 17% papers, accounting for the second largest citations share (23.04%), are covered in the citation range (200-399 times). Only 3.95% papers, accounting for 13.70% share of total 14059 citations during 2000-14, relate to top-end citation range (500-899 times). Nearly 2.63% papers, accounting for the smallest citations share (6.54%), cover midsection (400-999 times) of the citation range (Table 4, Figure 2 ).
Contribution of Top Cited Authors in Research
In all, 303 Indian and foreign authors contributed to 76 highly cited papers in clinical pharmacology. Of these, 222 were Indian and 81 foreign authors. The study revealed that most of highly cited papers were contributed by Indians in their role as first author. Amongst 303 authors, thirty three (10.89%) made contributions as first author, another set of thirty three (10.89%) made contributions as corresponding author, and sixty three (20.79%) contributed both as first author and corresponding author. Amongst 222 Indian authors, twenty nine (13.06%) made contributions as first author along with corresponding author, thirty one (13.96%) as sole author, and fifty three (23.87%) both as first author and corresponding author. Among 81 foreign authors, four (4.94%) contributed as corresponding author, two (2.47%) as first author and ten (12.35%) both as first author and corresponding author. Of the 222 Indian authors to highly cited papers, 73 were affiliated to universities, 54 authors to research institutions, 28 to institutes of national importance, 20 to pharmaceutical colleges, 8 to industrial enterprises, and 1 each to college, hospital and state government department. Authorship to 76 highly cited papers varied widely from 1 to 32 authors per paper with an average of 3.95 authors per paper; and the largest authorship to highly cited papers was 32 authors per paper. Most of highly cited papers were either joint author or multi author papers in clinical pharmacology. Sole authorship highly cited papers are relatively fewer.
The rising trend to highly cited papers with multiple-authorship indicates that quality research in clinical pharmacology is becoming more and more of a team based activity/ multi-institutional activity. Secondly, multiple-authorship seems to hold potential to influence relatively high to very high citations (Table 5, Figure 3 ). Of the 222 Indian authors, 208 contributed one paper each once in 15 years, 11 contributed two publications each once in 15 years; 1 contributed three papers in all 15 years. It shows that frequency of contribution to highly cited papers by Indian authors in clinical pharmacology is not significant. Top 12 authors, each contributing at least 2 highly cited papers, were ranked on volume of their output in clinical pharmacology (Table 6 ). Among the 76 highly cited papers, 37 papers had the participation of 1 organization each, 23 papers with 2 organizations each, 7 papers with 3 organizations each, 6 papers with 4 organizations each, 1 paper each with 5, 7 and 28 organizations (Table 9 ).
Collaboration in Highly Cited Papers
Of all the 76 highly cited publications in clinical pharmacology, 38 resulted with authorship to each of these papers belonging to co-authors from the same single parent organization only (labeled as publications with authorship by single Indian organization), 20 resulted from national collaboration with authorship to each of these papers belonging to 2 or more Indian organizations (labeled as national collaborative publications), and 18 resulted from international collaboration with authorship to each of these papers belonging to 2 or more Indian and foreign organizations (labeled as international collaborative publications) (Table 10) .
Internationally collaborative publications scored higher citation impact with 204.1 citations per publication compared to single institution publications with 199.6 citations per publication and national collaborative publications with 140.1 citations per publication (Table 10 ).
Contribution of Organizations: Single Institution Participation
In all, 38 highly cited papers resulted from participation of 24 Indian organizations and 113 authors; authorship to each of these 38 papers Their MCI index varies from 0.0 to 1.0. No correlation was found between their rank order and MCI index.
Contribution of Top Organizations in Research
In all 135 organizations (74 Indian and 61 foreign) had participated in contributing 76 highly cited papers in clinical pharmacology research in India during 2000-14. Of the 74 Indian research organizations, only 13 were comparatively more productive, with each contributing 2 to 7 highly cited papers in clinical pharmacology in 15 years during 2000-14.
The other 61 were low productivity organizations, with each contributing only one publication each during the same period. Research institutions dominated the publications output of highly cited papers in clinical pharmacology with largest share (36.84%, 28 papers), followed by universities (30.26% share, 23 papers), institutes of national importance and medical colleges (15.79% share, 12 papers each), pharmaceutical colleges and industrial enterprises (7.89% share, 6 papers each), engineering colleges (2.63% share, 2 papers), college, hospital and state government department (1.32% share, 1 paper each) during 2000-14 (Table 7) . MCI greater than 0.500 indicates that the institution has high potential to conduct research independently, contribute to research productivity Of the 82 authors in 20 papers, 35 were affiliated to universities, 18 to pharmaceutical colleges, 11 to medical colleges, 9 to research institutes, 5 to industrial enterprises, 2 to institutes of national importance, and 1 each to hospital and state government department. In terms of distribution of authorship to 20 papers, 3 were contributed by 2 authors each, 5 publications each by 3 and 4 authors each, 2 contributed by 5 authors each, 3 contributed by 6 authors each and 1 publication each contributed by 7 and 9 authors. The authorship to 20 papers averaged to 4.25 authors per publication. Of the 20 national collaborative publications, in 8 papers authors contributed both as first author and corresponding author, in 6 other authors contributed only as first author, and in another 6 authors contributed only as corresponding author.
TP=Total Papers; FP=Number of first-author top cited articles; RP=Number of corresponding top-cited articles
Contribution of Organization: International Collaborative Institutions
In 9 foreign authors participated both as first author and corresponding author, 3 as first author only and 5 as corresponding authors only. From India, 2 authors participated both as first author and corresponding author, 4 as first author and 2 as corresponding author only. The relative contribution of various foreign countries as first author and corresponding author publications is shown in Table 11 .
Medium of Communication
Journals play an important role in the communication structure of science. All of the 76 highly cited publications in Indian clinical pharmacology were published in 45 peer reviewed journals. No significant correlation was found between citation numbers of highly cited papers and the impact factor of their reporting journals (Table 12) Of 45 journals, 32 (71.11%) reported one highly cited publication each, 6 (13.33%) reported two publications each, 5 (11.11%) reported three publications each, 1 (2.22%) journal each reported eight and nine publications respectively. Table 15 lists (Table 14) .
Effect of Time Period on Citations Output
Citation life cycle of highly cited papers published in the time period 2000-10 exhibit two trends i) papers that exhibit typical early peak, reaching their citation peak in 5 years since publication (Thakkar, , ii) papers that exhibit delayed recognition, delayed citation peak, reaching their citation peak in 8 -10 years since publication. In overall, life cycle of highly cited papers (TC2014 > 100) lasted from 6 to 14 years and that they all enter decline in citation after reaching their peak. As can be seen, highly cited papers in clinical pharmacology effectively have dated life cycle but they differ significantly in their cumulative citations output (TC2014) ranging from 276 to 811 (Table 15 , Figure 4 ). It is significant to note that papers that were published in 2007-2010 had a more-rapid rise in citation numbers, and needed relatively fewer years to reach their citation peak. If such a trend continues, high percentile articles will certainly reach their citation peaks even faster and need relatively fewer years since their publication (Table 15, Figure 5 ).
DISCUSSION
This study analyses 76 highly cited papers in clinical pharmacology that India published during the period 2000-14.
The study covered only such papers that received at least 100 citations since their publication till August 2015. The publications and citations data for the study was sourced from Scopus database. Citation in research evaluation is viewed as an acknowledgement of intellectual debt and scientific progress. Highly cited papers illustrate high quality science and a useful tool for quality assessment of key (most influential) contributors to science and technology. USA dominates global leadership in clinical pharmacology with highest 61.41% share, followed by U K, Germany, Italy, and Canada with 6.41% -17.12% share to the world output of highly cited papers in clinical pharmacology during 2000-14. India ranked 10 th highest country with 1.45% share to the world output of highly cited papers, 9 th highest with 0.75% share of highly cited papers in the national output, and 7 th highest with 3.81% share to the world output of all of publications in clinical pharmacology including highly cited papers. 76 highly cited papers were published across 45 Indian and foreign journals. Nanomedicine published the largest number of the highly cited publications (9 papers, 11.84% share), followed by Journal of Ethnopharmacology Research institutions dominated the publications output of highly cited papers in clinical pharmacology with largest share (36.84%, 28 papers), followed by universities (30.26% share, 23 papers), institutes of national importance and medical colleges (15.79% share, 12 papers each), pharmaceutical colleges and industrial enterprises (7.89% share, 6 papers each), engineering colleges (2.63% share, 2 papers), college, hospital and state government department (1.32% share, 1 paper each) during 2000-14.
The leading organizations from India in clinical pharmacology research include National Institute of Pharmaceutical Education &Research, papers in clinical pharmacology is still missing. It remained range bound between 2 to 11 papers per year. Citation life cycle of highly cited papers exhibit two trends: i) papers that reach their citation peak early within 5 years of their publication. For example, papers published during 2007-2010 saw a more-rapid rise in citation numbers, and needed relatively fewer years to reach their citation peak, ii) papers that exhibit delayed recognition, delayed citation peak, reaching their citation peak in 8 -10 years since their publication. Thereafter they decline in citation numbers and follow a descending path. If such a trend continues, high percentile papers will certainly reach their citation peaks even faster than expected and would relatively need fewer years to their citation peak. Authorship to 76 highly cited papers varied widely from 1 to 32 authors per paper with an average of 3.95 authors per paper. Most of highly cited papers were either joint author or multi author papers in clinical pharmacology. Sole authorship highly cited papers were fewer. The multipleauthorship in highly cited papers signals a trend towards team based/ multi-institutional collaborative research and an effective approach to produce high quality research in clinical pharmacology. Amongst 303 authors to 76 highly cited papers, thirty three (10.89%) made contributions as first authors, thirty three (10.89%) made contributions as corresponding authors, and sixty three (20.79%) contributed 
